Yaowei Zhu

1.4k total citations
19 papers, 1.1k citations indexed

About

Yaowei Zhu is a scholar working on Immunology, Dermatology and Physiology. According to data from OpenAlex, Yaowei Zhu has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 8 papers in Dermatology and 6 papers in Physiology. Recurrent topics in Yaowei Zhu's work include Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (8 papers) and Asthma and respiratory diseases (6 papers). Yaowei Zhu is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (13 papers), Dermatology and Skin Diseases (8 papers) and Asthma and respiratory diseases (6 papers). Yaowei Zhu collaborates with scholars based in United States, Canada and Germany. Yaowei Zhu's co-authors include Honghui Zhou, Alice B. Gottlieb, Newman Yeilding, Shu Li, Charles Pendley, Mary Ann Mascelli, Hugh M. Davis, Bart Frederick, Martin A. Graham and Daniel E. Everitt and has published in prestigious journals such as Journal of Investigative Dermatology, Journal of the American Academy of Dermatology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Yaowei Zhu

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yaowei Zhu United States	14	843	380	221	208	141	19	1.1k
Talia M. Muram United States	11	775 0.9×	426 1.1×	116 0.5×	206 1.0×	175 1.2×	18	972
Stephen Calabro United States	8	727 0.9×	284 0.7×	88 0.4×	128 0.6×	72 0.5×	11	971
Bart Frederick United States	12	611 0.7×	204 0.5×	186 0.8×	188 0.9×	112 0.8×	19	1.0k
James Proulx United States	4	551 0.7×	295 0.8×	153 0.7×	275 1.3×	84 0.6×	4	827
Thomas Salko United States	5	1.3k 1.5×	720 1.9×	212 1.0×	333 1.6×	253 1.8×	5	1.6k
Luke Peterson United States	15	970 1.2×	477 1.3×	294 1.3×	480 2.3×	137 1.0×	59	1.3k
Gregory Kricorian United States	14	1.4k 1.6×	718 1.9×	290 1.3×	387 1.9×	278 2.0×	23	1.7k
Ming-Chun Hsu United States	9	1.5k 1.8×	824 2.2×	232 1.0×	323 1.6×	270 1.9×	14	1.7k
J.M.P.A. van den Reek Netherlands	20	785 0.9×	470 1.2×	75 0.3×	217 1.0×	186 1.3×	41	1.1k
T.N. Dam Denmark	14	753 0.9×	462 1.2×	57 0.3×	145 0.7×	126 0.9×	21	1.0k

Countries citing papers authored by Yaowei Zhu

Since Specialization

Citations

This map shows the geographic impact of Yaowei Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaowei Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaowei Zhu more than expected).

Fields of papers citing papers by Yaowei Zhu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaowei Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaowei Zhu. The network helps show where Yaowei Zhu may publish in the future.

Co-authorship network of co-authors of Yaowei Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Yaowei Zhu. A scholar is included among the top collaborators of Yaowei Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaowei Zhu. Yaowei Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Reich, Kristian, Kenneth B. Gordon, Bruce Strober, et al.. (2022). Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. Journal of the European Academy of Dermatology and Venereology. 36(12). 2393–2400. 20 indexed citations

Zhu, Yaowei, Yan Xu, Yanli Zhuang, et al.. (2020). Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. Clinical and Translational Science. 13(6). 1217–1226. 10 indexed citations

Zhou, Wangda, Chuanpu Hu, Yaowei Zhu, et al.. (2020). Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis. Clinical Pharmacology & Therapeutics. 109(1). 131–139. 3 indexed citations

Philipp, Sandra, Alan Menter, Arjen Nikkels, et al.. (2020). Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study. British Journal of Dermatology. 183(4). 664–672. 50 indexed citations

Lebwohl, Mark, Richard G. Langley, Yaowei Zhu, et al.. (2019). Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. Journal of the European Academy of Dermatology and Venereology. 33(11). 2082–2086. 7 indexed citations

Yao, Zhenling, Chuanpu Hu, Yaowei Zhu, et al.. (2018). Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis. The Journal of Clinical Pharmacology. 58(5). 613–627. 40 indexed citations

Landells, Ian, Colleen Marano, Shu Li, et al.. (2015). Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology. 73(4). 594–603. 166 indexed citations

Kavanaugh, Arthur, L. Puig, Alice B. Gottlieb, et al.. (2015). Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial. Arthritis Care & Research. 67(12). 1739–1749. 83 indexed citations

Zhu, Yaowei, Qingmin Wang, Bart Frederick, et al.. (2013). Comparison of the Pharmacokinetics of Subcutaneous Ustekinumab between Chinese and Non-Chinese Healthy Male Subjects across Two Phase 1 Studies. Clinical Drug Investigation. 33(4). 291–301. 19 indexed citations

10.

Lebwohl, Mark, Newman Yeilding, Philippe Szapary, et al.. (2010). Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. Journal of the American Academy of Dermatology. 63(4). 571–579. 99 indexed citations

11.

Brodmerkel, Carrie, Yaowei Zhu, Qun Jiao, et al.. (2010). Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions.. PubMed. 9(6). 677–83. 13 indexed citations

12.

Zhu, Yaowei, et al.. (2010). Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. International Journal of Clinical Pharmacology and Therapeutics. 48(12). 830–846. 23 indexed citations

13.

Zhu, Yaowei, Chuanpu Hu, Ming Lu, et al.. (2009). Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis. The Journal of Clinical Pharmacology. 49(2). 162–175. 135 indexed citations

14.

Zhou, Honghui, Chuanpu Hu, Yaowei Zhu, et al.. (2009). Population‐Based Exposure‐Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis. The Journal of Clinical Pharmacology. 50(3). 257–267. 50 indexed citations

15.

Gottlieb, Alice B., Kevin D. Cooper, Thomas S. McCormick, et al.. (2007). A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Current Medical Research and Opinion. 23(5). 1081–1092. 82 indexed citations

16.

Westhovens, René, Frédéric Houssiau, Johan Joly, et al.. (2006). A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis.. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 33(5). 847–53. 17 indexed citations

17.

Kauffman, Catharine Lisa, Eiko Toichi, Thomas S. McCormick, et al.. (2004). A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis. Journal of Investigative Dermatology. 123(6). 1037–1044. 212 indexed citations

18.

Desai, Pankaj B., John Duan, Yaowei Zhu, & Samir A. Kouzi. (1998). Human liver microsomal metabolism of paclitaxel and drug interactions. European Journal of Drug Metabolism and Pharmacokinetics. 23(3). 417–424. 64 indexed citations

19.

Roychowdhury, D., Pinkal Desai, & Yaowei Zhu. (1997). Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer.. PubMed. 24(4 Suppl 12). S12–37. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact